- Home
- ELVA vs TNXP Comparison
ELVA vs TNXP Comparison
Compare ELVA & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- TNXP
- Stock Information
- Founded
- ELVA 1996
- TNXP 2007
- Country
- ELVA Canada
- TNXP United States
- Employees
- ELVA N/A
- TNXP N/A
- Industry
- ELVA
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- ELVA
- TNXP Health Care
- Exchange
- ELVA Nasdaq
- TNXP Nasdaq
- Market Cap
- ELVA 91.8M
- TNXP 109.1M
- IPO Year
- ELVA N/A
- TNXP N/A
- Fundamental
- Price
- ELVA $2.68
- TNXP $17.82
- Analyst Decision
- ELVA Strong Buy
- TNXP Strong Buy
- Analyst Count
- ELVA 5
- TNXP 2
- Target Price
- ELVA $6.10
- TNXP $585.00
- AVG Volume (30 Days)
- ELVA 29.0K
- TNXP 935.0K
- Earning Date
- ELVA 05-12-2025
- TNXP 05-12-2025
- Dividend Yield
- ELVA N/A
- TNXP N/A
- EPS Growth
- ELVA N/A
- TNXP N/A
- EPS
- ELVA N/A
- TNXP N/A
- Revenue
- ELVA $43,693,000.00
- TNXP $10,094,000.00
- Revenue This Year
- ELVA $55.23
- TNXP $12.17
- Revenue Next Year
- ELVA $63.75
- TNXP $789.15
- P/E Ratio
- ELVA N/A
- TNXP N/A
- Revenue Growth
- ELVA N/A
- TNXP 29.94
- 52 Week Low
- ELVA $1.67
- TNXP $6.76
- 52 Week High
- ELVA $3.54
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- ELVA 60.67
- TNXP 51.34
- Support Level
- ELVA $2.46
- TNXP $14.33
- Resistance Level
- ELVA $2.63
- TNXP $22.25
- Average True Range (ATR)
- ELVA 0.13
- TNXP 1.95
- MACD
- ELVA 0.02
- TNXP -0.07
- Stochastic Oscillator
- ELVA 94.51
- TNXP 44.90
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.